The Prevalence of HTLV-III/LAV Antibodies among Intravenous Drug Users Attending Treatment Programs in California: A Preliminary Report

Norman Levy, James R. Carlson, Steven Hinrichs, Nicholas Lerche, Marc Schenker, Murray B. Gardner

Research output: Contribution to journalLetterpeer-review

14 Scopus citations

Abstract

To the Editor: Intravenous drug use is the primary risk factor in 17 percent of the cases of acquired immunodeficiency syndrome (AIDS) reported in the United States, and intravenous drug users constitute the second largest risk group after homosexual men.1 Recently, antibodies to human T-cell lymphotropic virus Type III/lymphadenopathy-associated virus (HTLV-III/LAV) were also detected in as many as 87 percent of patients undergoing drug detoxification who did not have diagnosed AIDS.2 3 4 Most AIDS cases associated with intravenous drug use, however, have occurred in the northeastern United States, with the greatest concentration in the New York City–New Jersey area.3 Similarly, most.

Original languageEnglish (US)
Pages (from-to)446
Number of pages1
JournalNew England Journal of Medicine
Volume314
Issue number7
DOIs
StatePublished - Feb 13 1986

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The Prevalence of HTLV-III/LAV Antibodies among Intravenous Drug Users Attending Treatment Programs in California: A Preliminary Report'. Together they form a unique fingerprint.

Cite this